Core Viewpoint - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. has received drug registration certificates for Acetate Triptorelin Injection and Agomelatine Tablets, marking a significant expansion into reproductive and mental health sectors [1][2][3][4] Drug Registration Details - Acetate Triptorelin Injection: - Formulation: Injection - Specification: 0.25mg - Registration Category: Class 4 chemical drug - Validity: 18 months - Approval Number: H20254895, valid until July 21, 2030 [1][3] - Agomelatine Tablets: - Formulation: Tablet - Specification: 25mg - Registration Category: Class 4 chemical drug - Validity: 18 months - Approval Number: H20255026, valid until July 28, 2030 [2][3] Clinical Advantages - Acetate Triptorelin: - Offers unique clinical advantages in assisted reproductive technology compared to other similar drugs, such as faster onset, better safety profile, shorter treatment cycles, and improved patient tolerance [3][4] - Agomelatine: - A novel antidepressant with a dual mechanism of action, it provides rapid sleep improvement without affecting daytime functioning, low risk of sexual dysfunction, minimal weight impact, and good tolerance [4] Strategic Impact - The approval of these products aligns with national policies on child-rearing subsidies and the inclusion of assisted reproduction in health insurance, enhancing the company's position in the reproductive and mental health markets [4]
江苏诺泰澳赛诺生物制药股份有限公司关于自愿披露注射用醋酸西曲瑞克、阿戈美拉汀片获得药品注册证书的公告